Platelet-enriched plasma and muscle strain injuries: Challenges imposed by the burden of proof

Bruce H. Hamilton, Thomas Best

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Objective: To review the evidence for the clinical utilization of autologous plasma products in the management of muscle strain injuries. Method: Systematic review using EMBASE and MEDLINE (up to March 2010). Results: There is no level 1, 2, and 3 evidence for the use of autologous plasma products in muscle strain injuries. Furthermore, significant methodological limitations impact on the interpretation of the few published studies in this field. Conclusions: Although basic science and the use of recombinant growth factors in animal models support the concept of applying growth factors to acute muscle injuries, it is unclear if this evidence can be directly translated to reflect outcomes from platelet-enriched plasma. There remain a large number of unanswered questions, including the principle questions regarding safety and efficacy, which require appropriate scientific investigation. It is incumbent on sports physicians wishing to enhance athlete care, together with researchers, to search for these answers.

Original languageEnglish (US)
Pages (from-to)31-36
Number of pages6
JournalClinical Journal of Sport Medicine
Volume21
Issue number1
DOIs
StatePublished - Jan 1 2011
Externally publishedYes

Fingerprint

Blood Platelets
Muscles
Intercellular Signaling Peptides and Proteins
Wounds and Injuries
MEDLINE
Athletes
Sports
Animal Models
Research Personnel
Physicians
Safety

Keywords

  • autologous plasma
  • muscle injury
  • platelet-enriched plasma
  • platelet-rich plasma

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Platelet-enriched plasma and muscle strain injuries : Challenges imposed by the burden of proof. / Hamilton, Bruce H.; Best, Thomas.

In: Clinical Journal of Sport Medicine, Vol. 21, No. 1, 01.01.2011, p. 31-36.

Research output: Contribution to journalArticle

@article{c283366a0ba84eeb8be95c9889df9a71,
title = "Platelet-enriched plasma and muscle strain injuries: Challenges imposed by the burden of proof",
abstract = "Objective: To review the evidence for the clinical utilization of autologous plasma products in the management of muscle strain injuries. Method: Systematic review using EMBASE and MEDLINE (up to March 2010). Results: There is no level 1, 2, and 3 evidence for the use of autologous plasma products in muscle strain injuries. Furthermore, significant methodological limitations impact on the interpretation of the few published studies in this field. Conclusions: Although basic science and the use of recombinant growth factors in animal models support the concept of applying growth factors to acute muscle injuries, it is unclear if this evidence can be directly translated to reflect outcomes from platelet-enriched plasma. There remain a large number of unanswered questions, including the principle questions regarding safety and efficacy, which require appropriate scientific investigation. It is incumbent on sports physicians wishing to enhance athlete care, together with researchers, to search for these answers.",
keywords = "autologous plasma, muscle injury, platelet-enriched plasma, platelet-rich plasma",
author = "Hamilton, {Bruce H.} and Thomas Best",
year = "2011",
month = "1",
day = "1",
doi = "10.1097/JSM.0b013e318205a658",
language = "English (US)",
volume = "21",
pages = "31--36",
journal = "Clinical Journal of Sport Medicine",
issn = "1050-642X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Platelet-enriched plasma and muscle strain injuries

T2 - Challenges imposed by the burden of proof

AU - Hamilton, Bruce H.

AU - Best, Thomas

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Objective: To review the evidence for the clinical utilization of autologous plasma products in the management of muscle strain injuries. Method: Systematic review using EMBASE and MEDLINE (up to March 2010). Results: There is no level 1, 2, and 3 evidence for the use of autologous plasma products in muscle strain injuries. Furthermore, significant methodological limitations impact on the interpretation of the few published studies in this field. Conclusions: Although basic science and the use of recombinant growth factors in animal models support the concept of applying growth factors to acute muscle injuries, it is unclear if this evidence can be directly translated to reflect outcomes from platelet-enriched plasma. There remain a large number of unanswered questions, including the principle questions regarding safety and efficacy, which require appropriate scientific investigation. It is incumbent on sports physicians wishing to enhance athlete care, together with researchers, to search for these answers.

AB - Objective: To review the evidence for the clinical utilization of autologous plasma products in the management of muscle strain injuries. Method: Systematic review using EMBASE and MEDLINE (up to March 2010). Results: There is no level 1, 2, and 3 evidence for the use of autologous plasma products in muscle strain injuries. Furthermore, significant methodological limitations impact on the interpretation of the few published studies in this field. Conclusions: Although basic science and the use of recombinant growth factors in animal models support the concept of applying growth factors to acute muscle injuries, it is unclear if this evidence can be directly translated to reflect outcomes from platelet-enriched plasma. There remain a large number of unanswered questions, including the principle questions regarding safety and efficacy, which require appropriate scientific investigation. It is incumbent on sports physicians wishing to enhance athlete care, together with researchers, to search for these answers.

KW - autologous plasma

KW - muscle injury

KW - platelet-enriched plasma

KW - platelet-rich plasma

UR - http://www.scopus.com/inward/record.url?scp=78651395469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651395469&partnerID=8YFLogxK

U2 - 10.1097/JSM.0b013e318205a658

DO - 10.1097/JSM.0b013e318205a658

M3 - Article

C2 - 21200168

AN - SCOPUS:78651395469

VL - 21

SP - 31

EP - 36

JO - Clinical Journal of Sport Medicine

JF - Clinical Journal of Sport Medicine

SN - 1050-642X

IS - 1

ER -